Last reviewed · How we verify
NPI-0052
At a glance
| Generic name | NPI-0052 |
|---|---|
| Also known as | Marizomib, MRZ |
| Sponsor | Celgene |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (PHASE3)
- Marizomib Central Nervous System (CNS) (PHASE2)
- Phase I Study of Marizomib + Panobinostat for Children With DIPG (PHASE1)
- Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma (PHASE2)
- Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma (PHASE2)
- Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab (PHASE1, PHASE2)
- Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer (PHASE1)
- Expanded Access for Marizomib
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPI-0052 CI brief — competitive landscape report
- NPI-0052 updates RSS · CI watch RSS
- Celgene portfolio CI